Sponsored
Novo Nordisk launches Wegovy in India, targets obesity treatment market, offers semaglutide-based weekly injection
Posted
Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks. Priced between Rs 17,345 and Rs 26,050 per month, the injectable drug targets India's large obese population. The company aims to create awareness and collaborate with stakeholders to combat obesity, citing its significant impact on India's GDP.
Search
Categories
- National
- International
- Business
- Technology
- Health
- Education
- Sports
- Entertainment
- Travel
- Environment
- Science
- Law
- Agriculture
- Real Estate
- Opinion
- Religion
- Weather
- Automotive
- Social Issues
- Culture
- Sci-Fi & Future
Read More
Heavy rain hits Lalitpur’s Tikathali area, residents urged to stay alert
KATHMAND: Heavy rainfall has been reported in the Tikathali area of Lalitpur today. According to...
Nepal Rastra Bank revises foreign exchange rates for Wednesday
KATHMANDU: The Nepal Rastra Bank (NRB) has released the official foreign currency exchange rates...